JP7818585B2 - 癌を治療するための組み合わせ療法 - Google Patents
癌を治療するための組み合わせ療法Info
- Publication number
- JP7818585B2 JP7818585B2 JP2023521357A JP2023521357A JP7818585B2 JP 7818585 B2 JP7818585 B2 JP 7818585B2 JP 2023521357 A JP2023521357 A JP 2023521357A JP 2023521357 A JP2023521357 A JP 2023521357A JP 7818585 B2 JP7818585 B2 JP 7818585B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- azd5305
- acceptable salt
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089195P | 2020-10-08 | 2020-10-08 | |
| US63/089,195 | 2020-10-08 | ||
| PCT/EP2021/077703 WO2022074124A1 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546362A JP2023546362A (ja) | 2023-11-02 |
| JP2023546362A5 JP2023546362A5 (https=) | 2024-09-20 |
| JP7818585B2 true JP7818585B2 (ja) | 2026-02-20 |
Family
ID=78293953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521357A Active JP7818585B2 (ja) | 2020-10-08 | 2021-10-07 | 癌を治療するための組み合わせ療法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230372333A1 (https=) |
| EP (1) | EP4225297B1 (https=) |
| JP (1) | JP7818585B2 (https=) |
| KR (1) | KR20230083291A (https=) |
| CN (1) | CN116194110B (https=) |
| AU (1) | AU2021356123B2 (https=) |
| BR (1) | BR112023005160A2 (https=) |
| CA (1) | CA3197056A1 (https=) |
| DK (1) | DK4225297T3 (https=) |
| ES (1) | ES3005507T3 (https=) |
| FI (1) | FI4225297T3 (https=) |
| HU (1) | HUE069249T2 (https=) |
| IL (1) | IL301687A (https=) |
| MX (1) | MX2023004156A (https=) |
| PL (1) | PL4225297T3 (https=) |
| PT (1) | PT4225297T (https=) |
| TW (1) | TW202228693A (https=) |
| WO (1) | WO2022074124A1 (https=) |
| ZA (1) | ZA202304965B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| US20230250428A1 (en) * | 2022-02-07 | 2023-08-10 | Alliance Of Cardiovascular Researchers | Method and composition for early detection of malignancies |
| IL316019A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| CN118973572A (zh) * | 2022-04-07 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN121464135A (zh) * | 2023-07-07 | 2026-02-03 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022541483A (ja) | 2019-07-19 | 2022-09-26 | アストラゼネカ・アクチエボラーグ | Ｐａｒｐ１阻害薬 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015184145A1 (en) * | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
-
2021
- 2021-10-06 TW TW110137116A patent/TW202228693A/zh unknown
- 2021-10-07 ES ES21794474T patent/ES3005507T3/es active Active
- 2021-10-07 DK DK21794474.3T patent/DK4225297T3/da active
- 2021-10-07 US US18/248,108 patent/US20230372333A1/en active Pending
- 2021-10-07 EP EP21794474.3A patent/EP4225297B1/en active Active
- 2021-10-07 KR KR1020237013320A patent/KR20230083291A/ko active Pending
- 2021-10-07 CN CN202180065599.5A patent/CN116194110B/zh active Active
- 2021-10-07 WO PCT/EP2021/077703 patent/WO2022074124A1/en not_active Ceased
- 2021-10-07 PT PT217944743T patent/PT4225297T/pt unknown
- 2021-10-07 MX MX2023004156A patent/MX2023004156A/es unknown
- 2021-10-07 CA CA3197056A patent/CA3197056A1/en active Pending
- 2021-10-07 JP JP2023521357A patent/JP7818585B2/ja active Active
- 2021-10-07 BR BR112023005160A patent/BR112023005160A2/pt unknown
- 2021-10-07 AU AU2021356123A patent/AU2021356123B2/en active Active
- 2021-10-07 IL IL301687A patent/IL301687A/en unknown
- 2021-10-07 HU HUE21794474A patent/HUE069249T2/hu unknown
- 2021-10-07 FI FIEP21794474.3T patent/FI4225297T3/fi active
- 2021-10-07 PL PL21794474.3T patent/PL4225297T3/pl unknown
-
2023
- 2023-05-04 ZA ZA2023/04965A patent/ZA202304965B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022541483A (ja) | 2019-07-19 | 2022-09-26 | アストラゼネカ・アクチエボラーグ | Ｐａｒｐ１阻害薬 |
Non-Patent Citations (1)
| Title |
|---|
| Phytomedicine，2018年，Vol.50，pp.88-98 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202304965B (en) | 2024-09-25 |
| HUE069249T2 (hu) | 2025-02-28 |
| EP4225297A1 (en) | 2023-08-16 |
| CA3197056A1 (en) | 2022-04-14 |
| BR112023005160A2 (pt) | 2023-04-18 |
| MX2023004156A (es) | 2023-05-03 |
| CN116194110B (zh) | 2025-06-17 |
| DK4225297T3 (da) | 2025-01-02 |
| ES3005507T3 (en) | 2025-03-14 |
| AU2021356123A1 (en) | 2023-06-08 |
| PL4225297T3 (pl) | 2025-03-17 |
| TW202228693A (zh) | 2022-08-01 |
| KR20230083291A (ko) | 2023-06-09 |
| PT4225297T (pt) | 2024-12-30 |
| AU2021356123B2 (en) | 2025-01-09 |
| WO2022074124A1 (en) | 2022-04-14 |
| FI4225297T3 (fi) | 2024-12-10 |
| IL301687A (en) | 2023-05-01 |
| EP4225297B1 (en) | 2024-10-23 |
| JP2023546362A (ja) | 2023-11-02 |
| CN116194110A (zh) | 2023-05-30 |
| US20230372333A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7818585B2 (ja) | 癌を治療するための組み合わせ療法 | |
| ES2818620T3 (es) | Derivados de azabencimidazol como inhibidores de pi3k beta | |
| CN106188138B (zh) | 一种二氨基嘧啶化合物及包含该化合物的组合物 | |
| EP4631942A1 (en) | Pan-kras degrading agent, and preparation method therefor and use thereof | |
| JP7244430B2 (ja) | Ｗｅｅ－１キナーゼ阻害剤として有用なピリミドピリミジノン | |
| JP6517979B2 (ja) | １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法 | |
| TW202417450A (zh) | 三環化合物及其用途 | |
| BR112021005513A2 (pt) | derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos | |
| CN117580839A (zh) | 抗癌核激素受体靶向化合物 | |
| WO2024110853A1 (en) | Solid forms of a fused pyridine for the treamtent of cancer | |
| WO2015113521A1 (zh) | 氘代喹唑啉酮化合物以及包含该化合物的药物组合物 | |
| TWI571470B (zh) | 磷醯胺酸前藥 | |
| US9975898B2 (en) | Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-YL)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one as tor kinase inhibitors | |
| CA3164682A1 (en) | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use | |
| EA049465B1 (ru) | Комбинированная терапия для лечения рака | |
| HK40099137B (en) | Combination therapy for treating cancer | |
| HK40099137A (en) | Combination therapy for treating cancer | |
| JP7053654B2 (ja) | ＰＩ３Ｋβ阻害剤としてのキノキサリン及びピリドピラジン誘導体 | |
| WO2025007950A1 (en) | Crystalline tnik inhibitor and uses thereof | |
| CN120904168A (zh) | 第四代egfr抑制剂、及其制备方法和在药学上的应用 | |
| HK40015557A (en) | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240911 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251223 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7818585 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |